Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04144140
Recruitment Status : Recruiting
First Posted : October 30, 2019
Last Update Posted : May 22, 2020
Sponsor:
Collaborator:
H3 Biomedicine Inc.
Information provided by (Responsible Party):
Eisai Inc.

Brief Summary:
This is an open label, multicenter, phase 1/1b study to assess safety/tolerability and preliminary clinical activity of E7766 as a single agent administered intratumorally in participants with advanced solid tumors or lymphomas.

Condition or disease Intervention/treatment Phase
Lymphoma Advanced Solid Tumors Drug: E7766 Phase 1

Detailed Description:
The Phase 1/1b study consist of two parts: Dose Escalation and Dose Expansion. In the Dose Escalation Part, E7766 will be administered intratumorally in participants with advanced solid tumors or lymphomas to assess safety/tolerability profile of E7766 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of E7766. In the Dose Expansion Part, E7766 at RP2D will be administered to participants with melanoma, head and neck squamous cell carcinoma (HNSCC), breast cancer, colorectal cancer, and/or other tumors including lymphomas to confirm safety and assess preliminary clinical activity of E7766 as a single agent. Clinical activity will be evaluated by objective response rate (ORR), duration of response (DOR), and disease control rate (DCR) on treatment with E7766.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Multicenter Phase 1/1b Study of Intratumorally Administered STING Agonist E7766 in Subjects With Advanced Solid Tumors or Lymphomas - INSTAL-101
Actual Study Start Date : March 19, 2020
Estimated Primary Completion Date : December 17, 2022
Estimated Study Completion Date : December 17, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: Dose Escalation: Advanced Solid Tumors or Lymphomas Drug: E7766
E7766, solution, intratumorally

Experimental: Dose Expansion: Advanced Solid Tumors or Lymphomas
Dose identified from dose escalation part for E7766 will be used in dose expansion part.
Drug: E7766
E7766, solution, intratumorally




Primary Outcome Measures :
  1. Dose Escalation Part: Number of Participants with Dose-limiting Toxicities (DLTs) [ Time Frame: Cycle 1 (Cycle length is equal to [=] 21 days) ]
    DLTs are any of the toxicities occurring during the Cycle 1 and assessed by the investigator as related to study drug. Toxicity will be evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v.5.0).

  2. Dose Escalation and Expansion Part: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Baseline up to 90 days after the last dose of study drug (approximately 3 years 1 month) ]
  3. Dose Expansion Part: Percentage of Participants With Objective Response [ Time Frame: From date of first dose of study drug until first documentation of complete response (CR) or partial response (PR) (up to approximately 3 years 1 month) ]
  4. Dose Expansion Part: Duration of Response (DOR) [ Time Frame: From first documented CR or PR until first documentation of recurrent or progressive disease or death (up to approximately 3 years 1 month)] ]
  5. Dose Expansion Part: Percentage of Participants With Disease Control [ Time Frame: From first dose of study drug until first documentation of CR or PR or stable disease (SD) (up to approximately 3 years 1 month) ]

Secondary Outcome Measures :
  1. Dose Escalation Part: Percentage of Participants With Objective Response [ Time Frame: From date of first dose of study drug until first documentation of CR or PR (up to approximately 3 years 1 month)] ]
  2. Dose Escalation Part: DOR [ Time Frame: From first documented CR or PR until first documentation of recurrent or progressive disease or death (up to approximately 3 years 1 month) ]
  3. Dose Escalation Part: Percentage of Participants With Disease Control [ Time Frame: From first dose of study drug until until first documentation of CR or PR or SD (up to approximately 3 years 1 month) ]
  4. Cmax: Maximum Observed Plasma Concentration for E7766 [ Time Frame: Dose Escalation:Cycle 1 Day 1: 0-24 hours;Cycle 1 Day 8: 0-2 hours;Cycle 1 Day 15: 0-24 hours; Cycle 2 Day 1 through Cycle 6 Day 1:0-2 hours;Dose Expansion:Cycle 1 Day 1: 0-2 hours; Cycle 1 Day 15: 0-2 hours; Cycle 2 Day 1:0-2 hours(Cycle length=21 days) ]
    In time frame ''0" hour signifies predose.

  5. Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for E7766 [ Time Frame: Dose Escalation:Cycle 1 Day 1: 0-24 hours;Cycle 1 Day 8: 0-2 hours;Cycle 1 Day 15: 0-24 hours; Cycle 2 Day 1 through Cycle 6 Day 1:0-2 hours;Dose Expansion:Cycle 1 Day 1: 0-2 hours; Cycle 1 Day 15: 0-2 hours; Cycle 2 Day 1:0-2 hours(Cycle length=21 days) ]
    In time frame ''0" hour signifies predose.

  6. AUC: Area Under the Plasma Concentration Versus Time Curve for E7766 [ Time Frame: Dose Escalation:Cycle 1 Day 1: 0-24 hours;Cycle 1 Day 8: 0-2 hours;Cycle 1 Day 15: 0-24 hours; Cycle 2 Day 1 through Cycle 6 Day 1:0-2 hours;Dose Expansion:Cycle 1 Day 1: 0-2 hours; Cycle 1 Day 15: 0-2 hours; Cycle 2 Day 1:0-2 hours(Cycle length=21 days) ]
    In time frame ''0" hour signifies predose.

  7. t1/2: Terminal Elimination Half-life for E7766 [ Time Frame: Dose Escalation:Cycle 1 Day 1: 0-24 hours;Cycle 1 Day 8: 0-2 hours;Cycle 1 Day 15: 0-24 hours; Cycle 2 Day 1 through Cycle 6 Day 1:0-2 hours;Dose Expansion:Cycle 1 Day 1: 0-2 hours; Cycle 1 Day 15: 0-2 hours; Cycle 2 Day 1:0-2 hours(Cycle length=21 days) ]
    In time frame ''0" hour signifies predose.

  8. CL/F: Apparent Total Body Clearance for E7386 [ Time Frame: Dose Escalation:Cycle 1 Day 1: 0-24 hours;Cycle 1 Day 8: 0-2 hours;Cycle 1 Day 15: 0-24 hours; Cycle 2 Day 1 through Cycle 6 Day 1:0-2 hours;Dose Expansion:Cycle 1 Day 1: 0-2 hours; Cycle 1 Day 15: 0-2 hours; Cycle 2 Day 1:0-2 hours(Cycle length=21 days) ]
    In time frame ''0" hour signifies predose.

  9. Vd/F: Apparent Volume of Distribution for E7766 [ Time Frame: Dose Escalation:Cycle 1 Day 1: 0-24 hours;Cycle 1 Day 8: 0-2 hours;Cycle 1 Day 15: 0-24 hours; Cycle 2 Day 1 through Cycle 6 Day 1:0-2 hours;Dose Expansion:Cycle 1 Day 1: 0-2 hours; Cycle 1 Day 15: 0-2 hours; Cycle 2 Day 1:0-2 hours(Cycle length=21 days) ]
    In time frame ''0" hour signifies predose.

  10. CLr: Renal Clearance for E7766 [ Time Frame: Dose Escalation:Cycle 1 Day 1: 0-24 hours;Cycle 1 Day 8: 0-2 hours;Cycle 1 Day 15: 0-24 hours; Cycle 2 Day 1 through Cycle 6 Day 1:0-2 hours;Dose Expansion:Cycle 1 Day 1: 0-2 hours; Cycle 1 Day 15: 0-2 hours; Cycle 2 Day 1:0-2 hours(Cycle length=21 days) ]
    In time frame ''0" hour signifies predose.

  11. R: Accumulation Ratio for E7766 [ Time Frame: Dose Escalation:Cycle 1 Day 1: 0-24 hours;Cycle 1 Day 8: 0-2 hours;Cycle 1 Day 15: 0-24 hours; Cycle 2 Day 1 through Cycle 6 Day 1:0-2 hours;Dose Expansion:Cycle 1 Day 1: 0-2 hours; Cycle 1 Day 15: 0-2 hours; Cycle 2 Day 1:0-2 hours(Cycle length=21 days) ]
    In time frame ''0" hour signifies predose.

  12. Dose Escalation Part: Fraction Excreted (fe) in Urine for E7766 [ Time Frame: Cycle 1 Day 1: 0-24 hours post dose;Cycle 1 Day 15: 0-24 hours post dose; (Cycle length=21 days) ]
    In time frame ''0" hour signifies predose.

  13. Dose Escalation Part: Fraction Excreted (fe) in Feces for E7766 [ Time Frame: Cycle 1 Day 1: 0-24 hours post dose (Cycle length=21 days) ]
    In time frame ''0" hour signifies predose.

  14. Dose Escalation and Dose Expansion: Progression Free Survival (PFS) [ Time Frame: From first dose of study drug until confirmed PD or death (up to approximately 3 years 1 month) ]
  15. Dose Escalation and Dose Expansion: Overall Survival (OS) [ Time Frame: From first dose of study drug until death (up to approximately 3 years 1 month) ]
  16. Dose escalation and Dose Expansion: Change in Tumor Size in Injected lesions and in Distant Non-injected Lesions [ Time Frame: Solid Tumor: Cycle 1 (C1) Day 1 (D1) pre-dose, every 6 weeks pre-dose from C1D1 up to approximately 3 years 1 month; Lymphoma: C1D1 pre-dose, Week 9 pre-dose, every 12 weeks pre-dose from CIDI up to approximately 3 years 1 month (Cycle length=21 days) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
  1. Participants with solid tumors or lymphomas, confirmed by available histopathology records or current biopsy, that are advanced, nonresectable, or recurrent and progressing since last antitumor therapy, and for which no alternative standard therapy exists.
  2. Participants must have a minimum of one injectable lesion which is also accessible for biopsy, and if available, one other measurable lesion also accessible for biopsy.

    An injectable lesion is defined as being measureable (defined below) with a maximum of 3.0 centimeter (cm) longest diameter, accessible for injection as judged by the investigator, and has not been subjected to any prior intratumoral treatment or radiotherapy. Lesions selected for injection must not be too close to a major vessel and not be associated with increased risk of bleeding, example, subcapsular liver lesions or hypervascular tumors.

    Measurable lesions are:

    1. Solid tumors: At least 1 lesion of greater than or equal to (>=1) cm by longest axial diameter or >=1.5 cm short axis diameter if a nodal lesion, which is serially measurable according to modified Response evaluation criteria in solid tumors (RECIST) 1.1 using CT/MRI or photography. Lesions that have had external beam radiotherapy or locoregional therapies such as radiofrequency (RF) ablation must show evidence of progression to be deemed a target lesion.
    2. Lymphoma: At least 1 lymph node with a longest diameter greater than (>)1.5 cm or an extranodal lesion with a longest diameter >1.0 cm
  3. Participants with prior Hepatitis B or C are eligible if they have adequate liver function
  4. Adequate bone marrow function:

    1. Absolute neutrophil count (ANC) >=1000 per cubic millimeter (/mm^3) (>=1.0*10^3 per microliter [/mcL])
    2. Platelets >=75,000/mm^3 (>=75*10^ 9 per liter [/L])
    3. Hemoglobin >=9.0 grams per deciliter (g/dL)
  5. Adequate liver function defined by:

    1. Adequate blood coagulation function as evidenced by an International Normalized Ratio (INR) less than or equal to (<=)1.5
    2. Total bilirubin <=1.5*upper limit of the normal range (ULN) except for unconjugated hyperbilirubinemia or Gilbert's syndrome
    3. Alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) <=3*ULN (in the case of liver metastasis <=5*ULN) unless there are bone metastases. Participants with ALP values >3*ULN and known to have bone metastases can be included.

Exclusion Criteria:

  1. Other malignancy active within the previous 2 years except for basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast that has completed curative therapy.
  2. Known human immunodeficiency virus (HIV) infection.
  3. Major surgery within 4 weeks before the first dose of study drug.
  4. Brain metastases that are untreated or in the posterior fossa or involve the meninges. Participants with stable or progressing brain metastases (except in the posterior fossa or involving the meninges) previously treated with brain stereotactic radiotherapy (SRT), whole-brain radiotherapy (WBRT) and/or surgery are allowed as long as the participant is asymptomatic neurologically and does not require immediate local intervention (radiotherapy and/or surgery). In addition, participants must be off immunosuppressive doses of systemic steroids (>10 milligram per day (mg/d) prednisone or equivalent) for at least 4 weeks before study drug administration.
  5. Prolongation of corrected QT (QTc) interval to >450 millisecond (msec) for males and females when electrolytes balance is normal.
  6. Females who are breastfeeding or pregnant at screening or baseline (as documented by a positive beta-human chorionic gonadotropin [ß-hCG] (or human chorionic gonadotropin [hCG]) test with a minimum sensitivity of 25 units per liter (IU/L) or equivalent units of ß-hCG [or hCG]). A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug.
  7. Females of childbearing potential must not have had unprotected sexual intercourse within 30 days before study entry and must agree to use a highly effective method of contraception (total abstinence [if it is their preferred and usual lifestyle], a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout the entire study period and for 180 days after study drug discontinuation. For sites outside of the European Union, it is permissible that if a highly effective method of contraception is not appropriate or acceptable to the participant, then the participant must agree to use a medically acceptable method of contraception, that is, double barrier methods of contraception such as condom plus diaphragm or cervical/vault cap with spermicide. If currently abstinent, the participant must agree to use a highly effective method as described above if she becomes sexually active during the study period or for 180 days after study drug discontinuation. Females who are using hormonal contraceptives must have been on a stable dose of the same hormonal contraceptive product for at least 28 days before dosing and must continue to use the same contraceptive during the study and for 180 days after study drug discontinuation.
  8. Male participants who are partners of women of childbearing potential must use a condom and spermicide and their female partners if of childbearing potential must use a highly effective method of contraception beginning at least 1 menstrual cycle prior to starting study drug(s), throughout the entire study period, and for 180 days after the last dose of study drug, unless the male participants are totally sexually abstinent or have undergone a successful vasectomy with confirmed azoospermia or unless the female partners have been sterilized surgically or are otherwise proven sterile. No sperm donation is allowed during the study period or for 180 days after study drug discontinuation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04144140


Contacts
Layout table for location contacts
Contact: Eisai Medical Information 1-888-274-2378 esi_oncmedinfo@eisai.com

Locations
Layout table for location information
United States, Connecticut
Yale Not yet recruiting
New Haven, Connecticut, United States, 06510
United States, Florida
Sylvester Cancer Center Recruiting
Miami, Florida, United States, 33136
United States, Massachusetts
MGH Recruiting
Boston, Massachusetts, United States, 02114
Beth Israel Deaconess Medical Center Recruiting
Boston, Massachusetts, United States, 02215
Center for Immuno-Oncology , DFCI Recruiting
Boston, Massachusetts, United States, 02215
United States, Pennsylvania
UPMC Recruiting
Pittsburgh, Pennsylvania, United States, 15232
France
Institut Gustave Roussy Recruiting
Villejuif, France, 94805
United Kingdom
Imperial College Healthcare NHS Trust Not yet recruiting
London, United Kingdom, W12 0HS
Sponsors and Collaborators
Eisai Inc.
H3 Biomedicine Inc.
Layout table for additonal information
Responsible Party: Eisai Inc.
ClinicalTrials.gov Identifier: NCT04144140    
Other Study ID Numbers: E7766-G000-101
2019-000160-17 ( EudraCT Number )
First Posted: October 30, 2019    Key Record Dates
Last Update Posted: May 22, 2020
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Eisai Inc.:
Advanced Solid Tumors
E7766
Intratumoral Injection
Stimulator of Interferon Genes Agonist
Interferons
Antineoplastic Agents
Lymphoma
Melanoma
Head and Neck Squamous Cell Carcinoma
Breast Cancer
Colorectal Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases